Domagrozumab
Domagrozumab is an experimental drug that was under development by Pfizer for the treatment of Duchenne muscular dystrophy. The drug is a humanized monoclonal antibody that targets myostatin, a protein that inhibits muscle growth. However, in August 2018, Pfizer announced that it was discontinuing the development of domagrozumab due to lack of efficacy.
History[edit | edit source]
Domagrozumab was initially developed by Pfizer as a potential treatment for Duchenne muscular dystrophy (DMD), a rare and severe form of muscular dystrophy. The drug was designed to target myostatin, a protein that inhibits muscle growth. By blocking the action of myostatin, it was hoped that domagrozumab could promote muscle growth and improve muscle function in people with DMD.
In 2012, Pfizer initiated a Phase 2 clinical trial to evaluate the safety and efficacy of domagrozumab in patients with DMD. However, in August 2018, Pfizer announced that it was discontinuing the development of the drug due to lack of efficacy. The decision was based on the results of an interim analysis of the Phase 2 trial, which showed that domagrozumab did not meet the primary efficacy endpoint.
Mechanism of Action[edit | edit source]
Domagrozumab is a humanized monoclonal antibody that targets myostatin, a protein that inhibits muscle growth. Myostatin is produced in skeletal muscle cells, circulates in the blood and acts on muscle tissue by binding to a cell-bound receptor called the activin type II receptor. Domagrozumab binds to myostatin and prevents it from binding to its receptor, thereby inhibiting its activity. This is expected to result in increased muscle mass and strength.
Clinical Trials[edit | edit source]
The Phase 2 clinical trial of domagrozumab was a randomized, double-blind, placebo-controlled study that enrolled patients with DMD. The primary endpoint of the trial was the change in total lean body mass (as measured by DEXA) from baseline to week 48. Secondary endpoints included changes in muscle strength, physical function, and quality of life.
Despite the initial promise, the trial did not meet its primary endpoint, leading to the discontinuation of the drug's development.
See Also[edit | edit source]
| Domagrozumab Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
